Clinical trial Recruiting at 3 sites Phase2; Phase3 Interventional Ages 18 to 75

Comparing Dry Needling and Botulinum Toxin for Post-Stroke Spasticity

Official title: Comparative Study of the Mechanism of Action of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity: a Proof of Concept Controlled Trial

Run by Universiteit Antwerpen · NCT06296082 · Data updated 2026-11-12

This study is testing whether dry needling can help reduce muscle tightness in the legs of stroke survivors just as well as a common injection treatment.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment90 (estimated)
SponsorUniversiteit Antwerpen
Academic / other
Locations3 sites (Antwerp, Flanders and 2 other locations)
StatusRecruiting
StartedSeptember 1, 2024
Main results expectedDecember 30, 2026
Study endsMarch 29, 2027
Registry record updatedMay 4, 2026
Trial IDNCT06296082 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-75 who have experienced their first stroke within the last 12 months and exhibit ankle plantar flexor spasticity.

Probably not a fit

Patients with medical conditions that interfere with data interpretation or those who have contraindications for BTX-A or DN treatment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a randomized parallel group study conducted in Spain, Canada, and Belgium, aimed at comparing the effectiveness of Botulinum Toxin type A (BTX-A) and Dry Needling (DN) in treating lower limb spasticity in patients who have experienced a first stroke within the last 12 months. Participants will be randomly assigned to receive either one session of BTX-A or 12 weekly sessions of DN. The study will assess the effects of these treatments on spasticity using blinded evaluators before, during, and after treatment, with a follow-up at four weeks. The primary hypothesis is that DN will have comparable effects to BTX-A in reducing spasticity by decreasing stretch reflex excitability.

Why it matters

Potential benefit: If successful, this study could provide an effective alternative treatment for post-stroke spasticity, improving mobility and quality of life for patients.

How similar studies have gone: Other studies have shown promising results with similar approaches, but this specific comparison of DN and BTX-A is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. aged 18-75 years.
2. post-stroke spasticity in ankle plantar flexors (Modified Ashworth Scale (MAS) scores of 1-2).
3. first stroke.
4. 0-12 months evolution.
5. no previous BTX-A or DN treatment for spasticity.
6. ankle passive range of motion ≥ 20° (approximately) with knee flexion \~30°.
7. independent ambulation with or without aids.

Exclusion Criteria:

1. medical conditions interfering with data interpretation.
2. contraindications for BTX-A or DN treatment.
3. changes in anti-spasticity medication dosage (if appropriate), either during the trial or within the 3 months prior to participation.
4. pregnant or breastfeeding.

Where it's running

  • Universiteit Antwerpen
    Antwerp, Flanders, Belgium
    Recruiting
  • Jewish Rehabilitation Hospital
    Montreal, Quebec, Canada
    Recruiting
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, Zaragoza, Spain
    Recruiting

Study contacts

  • Principal investigator: Pablo Herrero Gallego, PhD — Universidad de Zaragoza
  • Study coordinator: Pablo Herrero Gallego, PhD
  • Email: pherrero@unizar.es
  • Phone: +34646168248

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.